Next Biotech

Learn More about Next Investors - Experts in Biotech Stocks

Can New Cannabis Products Launch Creso Pharma Higher in 2020?

Next Investors Archived Dec 03, 2019

Through partnerships with leading global companies, Creso Pharma (ASX:CPH) has been able to, and will continue to accelerate the development and distribution of its products worldwide.

ASX Junior Has Early Success With K9 Cancer Trials: Human Trials Await

Next Investors Archived Nov 07, 2019

One ASX listed clinical stage oncology company is developing novel targeted cancer therapeutics for both humans and animals.

IMU Poised to Break into Oncolytic Virotherapy Space with Novel Cancer Therapy

Next Investors Archived Oct 24, 2019

The proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imugene (ASX:IMU) shareholders for their approval at an Extraordinary Meeting of Shareholders to be held on 18 November.

GTG Signs Prestigious Collaboration Agreement for Fight Against Cancer

Next Investors Archived Oct 02, 2019

Emerging med-tech junior Genetic Technologies (ASX:GTG | NASDAQ:GENE) understands the importance of timely and precise targeting. Accessible predictive risk testing is where GTG lives and it has now signed a 3-year Collaboration Agreement with high profile US-based researcher Translational Genomics Research Institute (TGen).

One ASX Med-Tech is Set to Transform The $100+Billion Cancer Diagnostic Market

Next Investors Archived Aug 14, 2019

MagSense is a unique, non-invasive, patent protected technology that fits into myriad addressable cancer diagnostic markets collectively worth $166 billion dollars and growing at 7% annually.

IMU’s Latest Cancer Treatment Acquisition Could Have Big Pharma Knocking

Next Investors Archived Jul 25, 2019

Imugene Limited (ASX:IMU) has negotiated to acquire a worldwide exclusive license to a promising OV developed at LA’s City of Hope Hospital.

Game Changer? ASX Stock Reverse Engineering Cannabis Plants

Next Investors Archived Jul 02, 2019

Who is the ASX company with transforming qualities that could completely disrupt the cannabis and CBD markets?

GTG Validates Cancer Tests As it Looks to Global Expansion

Next Investors Archived May 14, 2019

What if there was a cost effective way for patients to assess their cancer risk and seek treatment? There is. Genetic Technologies (ASX:GTG; NASDAQ:GENE).

ASX Med-Tech’s Genetic Cancer Screening Enters China, Eyes Future Asian Growth

Next Investors Archived Apr 08, 2019

Genetic Technologies (ASX:GTG) is a provider of world-leading genetic risk assessment test products.

Could a Loxo Oncology Style Trial, Bring Loxo Style Results for PTX?

Next Investors Archived Jan 31, 2019

Clinical stage oncology company, Prescient Therapeutics (ASX:PTX) is in a fortunate position. It has two clinical candidates, four trials, and multiple possible pathways to market for its targeted therapies that address specific mutations that drive cancer and contribute to resistance.

Imugene Meets All Endpoints in Phase 1b Gastric Cancer Immuno-oncology Trial

Next Investors Archived Dec 17, 2018

Imugene (ASX:IMU) has now released results from the Phase 1b Gastric Cancer trial, showing that all dose levels of its HER-Vaxx cancer vaccine showed an increase in antibodies in patients.

Zero Safety Issues for IMU’s Immunotherapy Cancer Treatment: Phase II Trial Imminent

Next Investors Archived Nov 13, 2018

Imugene (ASX:IMU) is a clinical stage life sciences company on the cutting edge of this very field and is developing vaccines to boost and direct the immune system to target and attack cancer cells.

ASX Biotech Eyes International Distribution of Overlooked Cancer Drug

Next Investors Archived Oct 30, 2018

Today’s biotech junior is in the business of repurposing late-stage drug assets that have been overlooked by big pharma.

Canada Legalises Cannabis as CPH Moves Front and Centre With a 100% Owned Canadian Growing Facility

Next Investors Archived Oct 18, 2018

This week, Canada has become the second country in the world — and the first industrialised nation — to legalise recreational cannabis use nationwide. ASX cannabis innovator, Creso Pharma (ASX:CPH), has welcomed this change with open arms.

ASX Junior’s Flagship Immunomodulatory Drug Could Turn the Tide in Duchenne Muscular Dystrophy Treatment

Next Investors Archived Oct 16, 2018

Duchenne muscular dystrophy (DMD) is a rare, yet fatal, muscular genetic condition that affects one in 3600 to 6000 male births worldwide. This ASX junior, capped at just $7 million, is already in a Phase II clinical trial with its flagship drug to treat DMD.

CPH has a Thirst for Bringing its Branded Cannabis Lifestyle Products to the World

Next Investors Archived Sep 05, 2018

Creso Pharma (ASX:CPH) is one step closer to launching its range of cannabis infused products.

IMC Ramps up DoD and CSIRO Partnerships in Quest to Supply Troops

Next Investors Archived Jul 17, 2018

Immuron Limited (ASX:IMC | NASDAQ:IMRN) has provided a steady stream of positive news across its microbiome immunotherapy platform — which includes assets that are preclinical, at clinical stage, and the already on-the-market Travelan® product.

MXC Moves Towards Commercial-Scale Pot Production with GMP Manufacturing Licence

Next Investors Archived Jul 13, 2018

Nimble ASX pot-stock MGC Pharmaceuticals (ASX:MXC) this week smashed a pivotal milestone, scoring full manufacturing licence for its world-class European compounding and manufacturing facility for the production of euGMP grade medicinal cannabis products.

< prev Page 3 of 7 next >